Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 881

TitleReference numberPublishedLast updated
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTA1045
Abaloparatide for treating osteoporosis after menopauseTA991
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Adalimumab for treating moderate to severe plaque psoriasisTA146
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis BTA96
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Aflibercept for treating choroidal neovascularisationTA486

Results per page

  1. 10
  2. 25
  3. 50
  4. All